Background We assessed the efficacy of a receptor-binding domain (RBD)-based protein
subunit COVID-19 vaccine. Methods A randomised Phase-1/2 trial followed by a Phase-2 trial …

Background After establishing safety and immunogenicity of Biological-E’s CORBEVAX™
vaccine in adult population (18–80 years) in Phase 1–3 studies, vaccine is further tested in …

The current scenario of typhoid fever warrants early prevention with typhoid conjugate
vaccines in susceptible populations to provide lifelong protection. We conducted a multicenter, …

Background We present the data from an open-label study involved in the selection of optimum
formulation of RBD-based protein sub-unit COVID-19 vaccine. Methods The randomized …

Optimum formulation of Biological-E’s protein subunit CORBEVAX™ vaccine was selected
in phase-1 and -2 studies and found to be safe and immunogenic in healthy adult population. …

Background Optimum formulation of Biological E’s CORBEVAX™ vaccine that contains
protein sub unit of Receptor Binding Domain (RBD) from the spike protein of SARS-COV-2 …

Background Measles is a major cause of childhood mortality and one-third of the world's
Measles deaths occur in India. Rubella causes lifelong birth defects (Congenital Rubella …

Background Vaccines developed against Covid-19 infection were effective in controlling
symptomatic infections and hospitalizations. However, waning immunity was reported within 6 …

Background: Japanese encephalitis (JE) is endemic in various parts of India. Due to the
limited treatment options available, a new treatment option that is safe and effective is highly …

Background: We present the data from an open-label study involved in the selection of
optimum formulation of RBD-based protein sub-unit COVID-19 vaccine. Methods: The …